Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.18−0.15 (-11.28%)
Close on Nov 13, 2026Market cap $118.40MP/E –Yield –
Cellectis operating margin
Operating margin is operating income as a percentage of revenue.
For fiscal 2025 it was -45.3%, against -143.5% the year before. The highest annual figure on record is -45.3% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -45.3% | +98.1 |
| FY2024 | Dec 31, 2024 | -143.5% | +12744.2 |
| FY2023 | Dec 31, 2023 | -12887.7% | −12420.0 |
| FY2022 | Dec 31, 2022 | -467.7% | −126.7 |
| FY2021 | Dec 31, 2021 | -341.0% | −258.1 |
| FY2020 | Dec 31, 2020 | -82.9% | +730.5 |
| FY2019 | Dec 31, 2019 | -813.4% | +12.1 |
| FY2018 | Dec 31, 2018 | -825.5% | −457.6 |
| FY2017 | Dec 31, 2017 | -367.8% | −217.6 |
| FY2016 | Dec 31, 2016 | -150.2% | −94.7 |
| FY2015 | Dec 31, 2015 | -55.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -449.8% | +1639.9 |
| Q2 FY2025 | Jun 30, 2025 | -57.3% | +278.1 |
| Q2 FY2024 | Jun 30, 2024 | -213.5% | +925.5 |
| Q2 FY2023 | Jun 30, 2023 | -13270.2% | −10221.1 |
| Q2 FY2022 | Jun 30, 2022 | -2089.7% | – |
| Q2 FY2021 | Jun 30, 2021 | -335.4% | – |
| Q2 FY2020 | Jun 30, 2020 | -1139.0% | – |
| Q2 FY2019 | Jun 30, 2019 | -3049.1% | – |
See a number that looks wrong?